4.5 Article

Gastrointestinal symptoms are predictive of trajectories of cognitive functioning in de novo Parkinson's disease

期刊

PARKINSONISM & RELATED DISORDERS
卷 72, 期 -, 页码 7-12

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.parkreldis.2020.01.009

关键词

Parkinson's disease; Mild cognitive impairment; Dementia; Gastrointestinal system; Microbiome

资金

  1. VA Career Development Award [IK2CX001717]
  2. Michael J. Fox Foundation for Parkinson's Research
  3. AbbVie
  4. Avid Radiopharmaceuticals
  5. Biogen Idec
  6. BioLegend
  7. Bristol-Meyers Squibb
  8. GE Healthcare
  9. Genentech
  10. GlaxoSmithKline
  11. Eli Lilly and Company
  12. Lundbeck
  13. Merck
  14. Meso Scale Discovery
  15. Pfizer Inc.
  16. Piramal Imaging
  17. Roche group
  18. Sanofi-Genzyme
  19. Servier
  20. Takeda
  21. TEVA
  22. UCB

向作者/读者索取更多资源

Introduction: Non-motor symptoms such as cognitive and gastrointestinal (GI) symptoms are common in Parkinson's disease (PD). In PD, GI-symptoms often present prior to motor symptoms. It is hypothesized that GI-symptoms reflect disruptions of the microbiome-gut-brain axis, which leads to altered immune functioning, chronic neuroinflammation, and subsequent neurodegeneration. Initial evidence links gut-dysbiosis to PD pathology and motor symptom severity. The present study examines the longitudinal relationship between severity of GI-symptoms and cognitive impairment in newly diagnosed PD patients. Methods: A secondary data analysis of the Parkinson's Progression Markers Initiative (PPMI) included 423 newly diagnosed PD patients who were followed for up to 5 years. Participants underwent neuropsychological tests of processing speed, attention, visuospatial functioning, verbal learning and verbal delayed recall. Participant were classified as cognitive intact, mild cognitive impairment or Parkinson's disease dementia. Frequency of GI-symptoms were assessed with the Scales for Outcomes in Parkinson's Disease Autonomic (SCOPA-AUT). Multilevel models (MLM) examined the longitudinal relationship between GI symptoms and cognitive impairment. Results: All cognitive outcomes were predicted by the main effect of GI symptoms, or the GI-symptom X Occasion interaction term. Specifically, more severe GI-symptoms were predictive of a less favorable trajectory of performance on tests of letter fluency, visuospatial, learning and memory. Cognitive performance was uniquely associated with GI-symptoms and unrelated to non-GI autonomic symptoms. Conclusions: The presence of GI symptoms may serve as an early marker of cognitive impairment in PD. Future studies should examine specific mechanisms underlying the relationship between gut-dysbiosis and cognitive impairment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据